Stifel Maintains Buy on Blueprint Medicines, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has maintained a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and increased the price target from $120 to $130.
April 26, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Bradley Canino reaffirmed a Buy rating on Blueprint Medicines and raised the price target to $130 from $120.
The increase in price target by Stifel reflects a positive outlook on Blueprint Medicines, suggesting confidence in the company's future performance. This analyst action can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100